<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10941">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614406</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU FAMPLAN 3854</org_study_id>
    <nct_id>NCT00614406</nct_id>
  </id_info>
  <brief_title>The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle</brief_title>
  <official_title>The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to test the hypothesis that the use of a prostaglandin inhibitor
      will result in premature luteolysis (ovulation failure) in women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently available methods of emergency contraception (EC) only work during a very narrow
      time period prior to the hormonal trigger for ovulation or the release of an egg. Women
      having unprotected sex outside this window receive no benefits from this emergency therapy.
      Prostaglandins are critical before, during, and after ovulation, thus their inhibition may
      cause an EC effect that works over a longer time period. We wanted to determine if celecoxib
      might work as an EC with a wider window of action.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Menstrual Cycle Length</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Menstrual cycle length was measured by the number of days subjects noted menstruating in their diary entry.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Ovulation (Follicular Rupture Yes/no)</condition>
  <condition>Menstrual Cycles (Total Length, Bleeding Days)</condition>
  <condition>Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex</intervention_name>
    <description>One 400mg tablet daily.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet daily.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-35

          -  Normal menstrual periods (24-35 days)

          -  Good general health

          -  Willing to use a non-hormonal form of contraception for the entire study (Acceptable
             forms of contraception include condoms, spermicide, sexual contact with a sterilized
             partner, subject is surgically sterile, same-sex partner, Copper IUD and abstinence)

          -  Willing and able to return to clinic for bi-weekly blood tests

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Polycystic ovarian disease

          -  Gastrointestinal conditions (i.e.gastric ulcer)

          -  Currently using birth control

          -  Known allergy to aspirin, non-steroidal anti-inflammatory drugs (NSAIDS) or
             Sulfa-drugs

          -  Diabetes

          -  Cardiac disease or hypertension

          -  Moderate to severe heartburn (GERD)

          -  Obesity (BMI greater than 30)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Edelman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 11, 2012</lastchanged_date>
  <firstreceived_date>January 31, 2008</firstreceived_date>
  <firstreceived_results_date>July 15, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>MD, MPH</investigator_title>
  </responsible_party>
  <keyword>Celebrex</keyword>
  <keyword>prostaglandin inhibitor</keyword>
  <keyword>ovulation</keyword>
  <keyword>menstrual cycles</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostaglandin Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential subjects may also have learned about the study from an OHSU Center for Womenâ€™s Health provider.Visit 1: reviewed of medical history and demographics and vital signs. A blood draw and urine pregnancy test was performed. Eligible subjects returned for the enrollment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Drug Cycle</title>
          <description>Group 1: control cycle, placebo cycle, active drug (celecoxib 400 mg orally, daily x1 menstrual cycle) cycle</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Group 2: control cycle, celecoxib cycle, placebo cycle orally, daily x1 menstrual cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Drug Cycle</title>
          <description>Group 1: control cycle, placebo cycle, active drug (celecoxib 400 mg orally, daily x1 menstrual cycle) cycle</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Group 2: control cycle, celecoxib cycle, placebo cycle orally, daily x1 menstrual cycle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27.3" spread="5.2"/>
                <measurement group_id="B2" value="28.8" spread="6.1"/>
                <measurement group_id="B3" value="27.85" spread="0.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Menstrual Cycle Length</title>
        <description>Menstrual cycle length was measured by the number of days subjects noted menstruating in their diary entry.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>Active drug(celecoxib 400 mg orally, daily for 1 menstrual cycle) cycle [cycle = length of menstrual cycle]</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cycle orally, daily x1 menstrual cycle [cycle = length of menstrual cycle]</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Menstrual Cycle Length</title>
            <description>Menstrual cycle length was measured by the number of days subjects noted menstruating in their diary entry.</description>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.5" spread="2.5"/>
                  <measurement group_id="O2" value="27.2" spread="2.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Drug Cycle</title>
          <description>Group 1: control cycle, placebo cycle, active drug (celecoxib 400 mg orally, daily x1 menstrual cycle) cycle</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Group 2: control cycle, celecoxib cycle, placebo cycle orally, daily x1 menstrual cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allison Edelman, MD, MPH</name_or_title>
      <organization>Oregon Health and Sciences University</organization>
      <phone>503-494-5949</phone>
      <email>edelmana@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
